Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...
Tharimmune Inc.: Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda ...
BioSpace2h
AstraZeneca Makes Up To $10B+ China Commitment Despite Political Pressure
The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...
Energage Names ACE a 2025 Top Workplaces USA Award Winner
The college has earned the honor for the past four years.